The ROE as of December 2024 (TTM) for Monopar Therapeutics Inc. (MNPR) is -21731.73%

According to Monopar Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -21731.73%. This represents a change of 228.66% compared to the average of -6612.18% of the last 4 quarters.

Monopar Therapeutics Inc. (MNPR) Historical ROE (quarterly & annually)

How has MNPR ROE performed in the past?

The mean historical ROE of Monopar Therapeutics Inc. over the last ten years is -73.36%. The current -21731.73% ROE has changed 29.52% with respect to the historical average. Over the past ten years (40 quarters), MNPR's ROE was at its highest in in the June 2016 quarter at 0%. The ROE was at its lowest in in the September 2024 quarter at -26366.12%.

Monopar Therapeutics Inc. (MNPR) ROE by Quarter and Year

Discovering the peaks and valleys of Monopar Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Monopar Therapeutics Inc. (MNPR) Average ROE

How has MNPR ROE performed in the past?

The current ROE of Monopar Therapeutics Inc. (MNPR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Monopar Therapeutics Inc. (MNPR) ROE vs. Peers

How is MNPR’s ROE compared to its peers?

Monopar Therapeutics Inc.’s ROE is less than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Acrivon Therapeutics, Inc. Common Stock (-47.95%), less than PMV Pharmaceuticals, Inc. (-24.20%), less than Molecular Partners AG (-39.16%), less than Mineralys Therapeutics, Inc. (-55.92%), less than Candel Therapeutics, Inc. (3.21%), greater than Acurx Pharmaceuticals, Inc. (-67679.28%), less than Enochian Biosciences, Inc. (-73.71%), greater than scPharmaceuticals Inc. (-314.97%), less than DiaMedica Therapeutics Inc. (-43.68%), less than Scopus BioPharma Inc. (911.69%), less than Pasithea Therapeutics Corp. (-81.66%), less than AN2 Therapeutics, Inc. (-57.63%), less than Pharvaris N.V. (-38.27%), less than PepGen Inc. (-60.17%), less than Aerovate Therapeutics, Inc. (-90.19%), less than Adagene Inc. (-50.10%), less than Rezolute, Inc. (-69.83%),

Build a custom stock screener for Monopar Therapeutics Inc. (MNPR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Monopar Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Monopar Therapeutics Inc. (MNPR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Monopar Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.